Cite
Aoki Y, Nojima M, Suzuki H, et al. Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. Genome Med. 2012;4(12):101doi: 10.1186/gm402.
Aoki, Y., Nojima, M., Suzuki, H., Yasui, H., Maruyama, R., Yamamoto, E., Ashida, M., Itagaki, M., Asaoku, H., Ikeda, H., Hayashi, T., Imai, K., Mori, M., Tokino, T., Ishida, T., Toyota, M., & Shinomura, Y. (2012). Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. Genome medicine, 4(12), 101. https://doi.org/10.1186/gm402
Aoki, Yuka, et al. "Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma." Genome medicine vol. 4,12 (2012): 101. doi: https://doi.org/10.1186/gm402
Aoki Y, Nojima M, Suzuki H, Yasui H, Maruyama R, Yamamoto E, Ashida M, Itagaki M, Asaoku H, Ikeda H, Hayashi T, Imai K, Mori M, Tokino T, Ishida T, Toyota M, Shinomura Y. Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. Genome Med. 2012 Dec 22;4(12):101. doi: 10.1186/gm402. eCollection 2012. PMID: 23259664; PMCID: PMC4064317.
Copy
Download .nbib